Liver TransplantationHCCNCT07703735
Survival and Recurrence After ABO-Incompatible Living Donor Liver Transplantation for Hepatocellular Carcinoma
An observational study of Liver Transplantation and Hepatocellular Carcinoma (HCC), run by Seoung Hoon Kim.
Trial summary
This retrospective cohort study aimed to evaluate long-term oncologic outcomes after ABO-incompatible living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC). Patients who underwent LDLT between January 2012 and December 2023 at a single tertiary center were included. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Liver Transplantation, Hepatocellular Carcinoma (HCC)
- How many people
- 371 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2012to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This study included consecutive adult patients who underwent living donor liver transplantation for hepatocellular carcinoma at the National Cancer Center, Korea. Patients were stratified according to ABO compatibility.
Who may be able to join
- Underwent living donor liver transplantation for HCC
- Transplantation between Jan 2012 - Dec 2023
Who cannot join
- • Deceased donor liver transplantation
- Re-transplantation
About this study
This retrospective cohort study aimed to evaluate long-term oncologic outcomes after ABO-incompatible living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC). Patients who underwent LDLT between January 2012 and December 2023 at a single tertiary center were included. Outcomes of interest included overall survival and recurrence patterns, with a focus on differences in time to recurrence between ABO-compatible and ABO-incompatible recipients.
Read the detailed description
This study included consecutive adult patients who underwent living donor liver transplantation for hepatocellular carcinoma at the National Cancer Center, Korea. Patients were stratified according to ABO compatibility. The primary outcomes were overall survival and time to recurrence. Survival outcomes were estimated using the Kaplan-Meier method, and risk factors for recurrence were analyzed using Cox proportional hazards regression models. The study aimed to assess whether ABO incompatibility affects long-term survival and recurrence patterns following LDLT.
- Medical subject headings
- Carcinoma, Hepatocellular
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival, Recurrence-free Survival
Time from liver transplantation until death from any cause
Measured: Up to 10 years after transplantation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study start1 Jan 2012
- Primary completion31 Dec 2025
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver TransplantationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 371 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Seoung Hoon Kim
- Sponsor type
- Other government
- Responsible party
- Sponsor-investigator, Seoung Hoon Kim, National Cancer Center, Korea
- Investigators
- Seoung Hoon Kim, MD, PhD, Principal investigator, National Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07703735
- Sponsor's protocol ID
- NCC 2025-0318
- Acronym
- HCC
- Status last verified
- Jul 2026
- First submitted
- 7 Jul 2026
- Last updated
- 14 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The data that support the findings of this study are not publicly available due to institutional and ethical restrictions but are available from the corresponding author on reasonable request and with permission from the institution.
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Survival and Recurrence After ABO-Incompatible Living Donor Liver Transplantation for Hepatocellular Carcinoma
- ClinicalTrials.gov ID
- NCT07703735
- Acronym / sponsor ID
- HCC / NCC 2025-0318
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 371 participants (estimated)
- Lead sponsor
- Seoung Hoon KimOther government
- Study start
- 1 Jan 2012 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 14 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This retrospective cohort study aimed to evaluate long-term oncologic outcomes after ABO-incompatible living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC). Patients who underwent LDLT between January 2012 and December 2023 at a single tertiary center were included. Outcomes of interest included overall survival and recurrence patterns, with a focus on differences in time to recurrence between ABO-compatible and ABO-incompatible recipients.
Detailed description
This study included consecutive adult patients who underwent living donor liver transplantation for hepatocellular carcinoma at the National Cancer Center, Korea. Patients were stratified according to ABO compatibility. The primary outcomes were overall survival and time to recurrence. Survival outcomes were estimated using the Kaplan-Meier method, and risk factors for recurrence were analyzed using Cox proportional hazards regression models. The study aimed to assess whether ABO incompatibility affects long-term survival and recurrence patterns following LDLT.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This study included consecutive adult patients who underwent living donor liver transplantation for hepatocellular carcinoma at the National Cancer Center, Korea. Patients were stratified according to ABO compatibility.
Key inclusion criteria (2 listed)
- Underwent living donor liver transplantation for HCC
- Transplantation between Jan 2012 - Dec 2023
Key exclusion criteria (2 listed)
- • Deceased donor liver transplantation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall Survival, Recurrence-free Survival
Time frame: Up to 10 years after transplantation
Time from liver transplantation until death from any cause
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2026.
- Individual participant dataSharing planned: Undecided. The data that support the findings of this study are not publicly available due to institutional and ethical restrictions but are available from the corresponding author on reasonable request and with permission from the institution.
Related trials for Liver Transplantation
Not yet recruitingObservational study
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
Not yet recruiting
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Hepatic Steatosis, Fatty Liver
Not yet recruiting
New Biomarkers for Organ Viability Assessment During Hypothermic Machine Perfusion in Liver Transplantation: the Role of Extemporaneous Histological Examination.
Liver Transplantation (LT), Early Allograft Dysfunction
RecruitingPhase 2
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
Liver Transplant
RecruitingObservational study
Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)
Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Seoung Hoon Kim, MD, PhD principal investigator
National Cancer Center
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Transplantation and Hepatocellular Carcinoma (HCC), run by Seoung Hoon Kim.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 14 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival, Recurrence-free Survival (time frame: Up to 10 years after transplantation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2026.